Anika Therapeutics, Inc.
Anika Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 38 | 41 | 57 | 58 | 53 | 53 | 56 | 62 | 63 | 69 | 69 | 71 | |||||
Marketable Securities Current | - | 26 | 24 | 22 | 24 | 22 | 24 | 28 | 34 | 32 | 26 | 35 | |||||
Accounts Receivable Net Current | 29 | - | - | - | - | - | - | - | - | - | - | - | |||||
Inventory Net | 29 | 23 | 19 | 16 | 17 | 21 | 24 | 40 | 51 | 49 | 24 | 44 | |||||
Prepaid Expense And Other Assets Current | 3 | 4 | 3 | 5 | 5 | 6 | 5 | 6 | 7 | 9 | 7 | 8 | |||||
Assets Of Disposal Group Including Discontinued Op… | - | - | 0 | 0 | 0 | 0 | 5 | - | - | - | 36 | - | |||||
Assets Current | 99 | 94 | 103 | 102 | 99 | 103 | 114 | 136 | 155 | 159 | 163 | 157 | |||||
Property Plant And Equipment Net | 40 | 40 | 40 | 41 | 41 | 40 | 39 | 45 | 48 | 46 | 37 | 46 | |||||
Operating Lease Right Of Use Asset | 25 | 25 | 26 | 24 | 25 | 25 | 26 | 27 | 28 | 28 | 28 | 29 | |||||
Other Assets Noncurrent | 3 | 4 | 4 | 6 | 6 | 6 | 6 | 11 | 20 | 18 | 6 | 19 | |||||
Deferred Income Tax Assets Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 69 | |||||
Goodwill | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 8 | 7 | 7 | 8 | 7 | |||||
Disposal Group Including Discontinued Operation As… | - | - | 0 | 0 | 0 | 0 | 2 | - | - | - | 25 | - | |||||
Assets | 183 | 179 | 190 | 189 | 188 | 191 | 203 | 231 | 263 | 264 | 271 | 328 | |||||
Liabilities Current | |||||||||||||||||
Accounts Payable Current | 6 | 6 | 6 | 5 | 5 | 5 | 6 | 7 | 10 | 10 | 6 | 8 | |||||
Accrued Liabilities And Other Liabilities | 16 | 15 | 16 | 14 | 11 | 13 | 14 | 19 | 16 | 18 | 14 | 20 | |||||
Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | 0 | 2 | |||||
Liabilities Of Disposal Group Including Discontinu… | - | - | 0 | 0 | 0 | 0 | 4 | - | - | - | 11 | - | |||||
Liabilities Current | 22 | 21 | 22 | 19 | 16 | 18 | 23 | 25 | 26 | 28 | 31 | 28 | |||||
Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | 23 | 24 | 24 | 23 | 23 | 24 | 24 | 25 | 26 | 26 | 26 | 27 | |||||
Equity | |||||||||||||||||
Liabilities Of Disposal Group Including Discontinu… | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | 1 | - | |||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 83 | 83 | 87 | 91 | 89 | 88 | 89 | 92 | 93 | 91 | 90 | 86 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -5 | -5 | -5 | -5 | -5 | -6 | -7 | -6 | -6 | -6 | -6 | -7 | |||||
Retained Earnings Accumulated Deficit | 59 | 56 | 61 | 60 | 63 | 67 | 72 | 94 | 123 | 124 | 128 | 191 | |||||
Stockholders Equity | 137 | 134 | 143 | 147 | 148 | 148 | 154 | 180 | 210 | 209 | 212 | 270 | |||||
Liabilities And Stockholders Equity | 183 | 179 | 190 | 189 | 188 | 191 | 203 | 231 | 263 | 264 | 271 | 328 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Preferred Stock Shares Authorized | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Common Stock Shares Authorized | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | |||||
Common Stock Shares Issued | 16 | 16 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | |||||
Shares Outstanding | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 15 | 15 | 15 | 15 | 15 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.52% | 15.82% | 22.49% | - | - | - | - | - | - | - | - | - |
| 2025 | -4.21% | -7.73% | -1.20% | 19.14% | 9.88% | 13.21% | 0.30% | -3.05% | -5.48% | -0.83% | 6.74% | 3.33% |
| 2024 | -9.91% | -11.03% | -2.00% | 0.08% | -4.36% | -5.30% | 3.81% | -4.86% | -4.45% | -15.33% | -27.75% | -29.55% |
| 2023 | - | - | - | -14.39% | -11.50% | -11.97% | 0.47% | 10.32% | 5.30% | 0.71% | 8.45% | 0.83% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 4.48 | 4.46 | 4.72 | 5.32 | 6.18 | 5.73 | 4.88 | 5.34 | 5.93 | 5.59 | 5.26 | 5.59 | |||||
| Quick Ratio | 3.05 | 3.19 | 3.71 | 4.20 | 4.80 | 4.21 | 3.62 | 3.56 | 3.70 | 3.54 | 4.23 | 3.75 | |||||
| Working Capital | 77.04M | 72.60M | 81.45M | 82.50M | 83.24M | 84.61M | 90.35M | 110.61M | 128.88M | 130.50M | 132.25M | 128.71M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 0.16 | 0.16 | 0.15 | 0.13 | 0.11 | 0.12 | 0.15 | 0.14 | 0.12 | 0.14 | 0.15 | 0.10 | |||||
| Interest Coverage TTM | -2.32 | -6.14 | -6.34 | -5.23 | -5.20 | -3.19 | -2.18 | 9.36 | 5.30 | 4.61 | 0.37 | -15.18 | |||||
| Debt Ratio | 0.12 | 0.12 | 0.12 | 0.10 | 0.09 | 0.09 | 0.11 | 0.11 | 0.10 | 0.11 | 0.11 | 0.09 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.65 | 0.63 | 0.57 | 0.54 | 0.51 | 0.52 | 0.51 | 0.31 | 0.33 | 0.37 | 0.39 | 0.48 | |||||
| Days Sales Outstanding TTM | 87.92 | - | - | - | - | - | - | - | - | - | - | - | |||||
| Receivables Turnover TTM | 4.15 | - | - | - | - | - | - | - | - | - | - | - | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.28 | -0.82 | -0.76 | -2.29 | -4.18 | -3.97 | -3.83 | -6.60 | -4.99 | -5.23 | -5.64 | -1.68 | |||||
| Free Cash Flow Per Share TTM | 0.04 | 0.08 | 0.30 | 0.04 | -0.04 | -0.23 | -0.16 | -0.05 | -0.31 | -0.67 | -0.88 | -1.14 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 62.16% | 58.59% | 56.56% | 54.74% | 57.25% | 61.26% | 63.38% | 74.82% | 71.39% | 70.30% | 68.33% | 61.78% | |||||
| Operating Profit Margin TTM | -4.24% | -10.54% | -9.80% | -10.99% | -8.08% | -5.88% | -4.25% | 23.50% | 12.93% | 9.73% | 0.70% | -18.69% | |||||
| Net Profit Margin TTM | -3.14% | -9.52% | -9.64% | -29.29% | -52.93% | -48.48% | -47.02% | -112.86% | -75.45% | -68.67% | -68.44% | -15.05% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | 5.33% | -0.67% | -5.91% | 30.55% | 16.51% | 4.61% | -0.73% | -47.09% | -39.36% | -28.94% | -22.69% | 7.14% | |||||
| Net Income Growth (1Y) | -93.76% | -80.50% | -80.70% | -66.12% | -18.27% | -26.14% | -31.79% | 296.83% | 234.53% | 244.90% | 456.34% | 56.09% | |||||
| EPS Growth (1Y) | -93.27% | -79.40% | -80.19% | -65.30% | -15.57% | -24.07% | -32.09% | 293.25% | 231.12% | 243.85% | 452.74% | 55.75% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -51.54 | -17.73 | -12.67 | -4.10 | -2.51 | -3.79 | -4.30 | -3.74 | -5.07 | -4.86 | -4.02 | -11.09 | |||||
| P/B TTM | 1.42 | 1.47 | 0.96 | 0.92 | 1.03 | 1.45 | 1.57 | 2.03 | 1.79 | 1.79 | 1.56 | 1.01 | |||||
| P/S TTM | 1.62 | 1.69 | 1.22 | 1.20 | 1.33 | 1.84 | 2.02 | 4.22 | 3.82 | 3.34 | 2.75 | 1.67 | |||||
| Market Cap | 195.02M | 196.20M | 137.80M | 135.54M | 151.97M | 214.88M | 242.31M | 364.77M | 375.87M | 373.33M | 332.10M | 272.65M | |||||
| Enterprise Value | 156.61M | 155.18M | 80.32M | 77.55M | 98.80M | 161.51M | 186.68M | 302.40M | 313.05M | 304.70M | 263.36M | 202.00M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 562.00K | 1.04M | 4.36M | 648.00K | -535.00K | -3.35M | -2.33M | -808.00K | -4.56M | -9.83M | -12.91M | -16.75M | |||||
| Net Debt | -38.41M | -41.02M | -57.48M | -57.99M | -53.17M | -53.37M | -55.63M | -62.37M | -62.82M | -68.63M | -68.74M | -70.65M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Anika Therapeutics, Inc. (ANIK) — SEC Financial Statements & Analysis
Anika Therapeutics, Inc. (ANIK) is a surgical & medical instruments & apparatus company, incorporated in DE. Anika Therapeutics, Inc. trades on Nasdaq as: ANIK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Anika Therapeutics, Inc. reported a 5.33% year-over-year revenue growth, a Gross Profit Margin of 62.16% (TTM), a Debt-to-Equity ratio of 0.16x, a Price-to-Sales (P/S) ratio of 1.62x (TTM), a Price-to-Book (P/B) ratio of 1.42x (TTM), at a market cap of $195.02M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- 5.33%
- Gross Profit Margin TTM
- 62.16%
- Debt To Equity
- 0.16x
- P/S TTM
- 1.62x
- P/B TTM
- 1.42x
- Market Cap
- $195.02M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Anika Therapeutics, Inc. in?
Anika Therapeutics, Inc. (ANIK) operates in the Surgical & Medical Instruments & Apparatus industry.
What is ANIK's market cap?
Anika Therapeutics, Inc. (ANIK) has a market capitalization of $195.02M as of 2026-06-30.
What exchange does ANIK trade on?
Anika Therapeutics, Inc. (ANIK) trades on the Nasdaq.
Where is Anika Therapeutics, Inc. incorporated?
Anika Therapeutics, Inc. is incorporated in DE.